ПРОФИЛАКТИКА И МОНИТОРИНГ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ ЛЮМИНАЛЬНЫМ HER2-ОТРИЦАТЕЛЬНЫМ МЕТАСТАТИЧЕСКИМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Дисфункция миокарда, сердечная недостаточность и удлинение интервала QTc могут являться опасными и значимыми кардиоваскулярными осложнениями в процессе системного лечения больных с люминальным HER2-отрицательным метастатическим раком молочной железы. Контроль развития подобных осложнений требует проведения специального мониторинга, особенно при внедрении в практику новых лекарственных препаратов. Знание особенностей развития, диагностики, профилактики и лечения кардиоваскулярных осложнений является важным для выбора оптимальной тактики ведения больных.

1. Здравоохранение в России. 2017: стат. сб. М.: Росстат, 2017. 170 с. [Health care in Russia 2017: statistical compendium. Moscow: Rosstat, 2017. 170 p. (In Russ.)].

2. Patnaik J.L., Byers T., DiGuiseppiet C. et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011;103(14):1101–11. PMID: 21719777. DOI: 10.1093/jnci/djr188.

3. Weaver L.C., Jessup A., Mayer D.K. Cancer survivorship care: implications for primary care advanced practice nurses. Nurse Pract 2013;38(11):1–11. PMID: 24141542. DOI: 10.1097/ 01.NPR.0000435784.40143.62.

4. Darby S.C., Ewertz M., McGale P. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. PMID: 23484825. DOI: 10.1056/NEJMoa1209825.

5. Darby S.C., McGale P., Taylor C.W. et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005;6(6):557–65. PMID: 16054566. DOI: 10.1016/S1470–2045(05) 70251–5.

6. EBCTC(Early Breast Cancer Trialists» Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: metaanalysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383(9935):2127–35. PMID: 24656685. DOI: 10.1016/S0140-6736(14)60488-8.

7. De Moor J.S., Mariotto A.B., Parry C. et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013;22(4):561–70. PMID: 23535024. DOI: 10.1158/1055-9965. EPI-12-1356.

8. Chapman J.A., Meng D., Shepherd L. et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008;100(4):252–60. PMID: 18270335. DOI: 10.1093/jnci/djn014.

9. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H. et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952–60. PMID: 17971593. DOI: 10.1200/JCO.2006.08.0499.

10. Colzani E., Liljegren A., Johansson A.L. et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age and tumor characteristics. J Clin Oncol 2011;29(30):4014–21. PMID: 21911717. DOI: 10.1200/JCO.2010.32.6462.

11. Bradshaw P.T., Stevens J., Khankari N. et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology 2016;27(1):6–13. PMID: 26414938. DOI: 10.1097/ EDE.0000000000000394.

12. Zamorano J.L., Lancellotti P., Rodriguez Munoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37(36): 2768–801. PMID: 27567406. DOI: 10.1093/eurheartj/ehw211.

13. Riccioa G., Coppolaa C., Piscopoa G. et al. Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Hum Vaccin Immunother 2016;12(5):1124–31. PMID: 26836985.DOI: 10.1080/ 21645515.2015.1125056.

14. Овчинников А.Г., Скоробогатова А.В., Семиглазова Т.Ю., Козявин Н.А. и др. Кардиотоксическое действие трастузумаба: механизмы развития, диагностика, лечение. Вопросы онкологии 2016;6:719–31. [Ovchinnikov A.G., Skorobogatova A.V., Semiglazova T.Yu., Kozyavin N.A. et al. Cardiotoxicity trastuzumab: mechanisms of development, diagnosis, treatment. Voprosy onkologii = Problems in Oncology 2016;6:719–31. (In Russ.)].

15. Gottdiener J.S., Appelbaum F.R., Ferrans V.J. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981;141(6):758–63. PMID: 7235784.

16. Mackey J.R., Martin M., Pienkowski T. et al. TRIO/BCIRG 001 Investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013;14(1):72–80. PMID: 23246022. DOI: 10.1016/S1470-2045(12)70525-9.

17. Gollerkeri A., Harrold L., Rose M. et al. Use of paclitaxel in patients with preexisting cardiomyopathy: a review of our experience. Int J Cancer 2001;93(1):139–41. PMID: 11391633.

18. Thavendiranathan P., Grant A.D., Negishi T. et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61(1):77–84. PMID: 23199515. DOI: 10.1016/j.jacc.2012.09.035.

19. Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28(1):1–39. PMID: 25559473. DOI: 10.1016/j.echo.2014.10.003.

20. Plana J.C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15(10):1063–93. PMID: 25239940. DOI: 10.1093/ehjci/jeu192.

21. Cardinale D., Colombo A., Lamantia G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55(3):213–20. DOI: 10.1016/j.jacc.2009.03.095.

22. Negishi K., Negishi T., Hare J.L. et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26(5):493–8. PMID: 23562088. DOI: 10.1016/j.echo.2013.02.008ю

23. Voigt J.U., Pedrizzetti G., Lysyansky P. et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging 2015;16(1):1–11. PMID: 25525063. DOI: 10.1093/ehjci/jeu184.

24. Jolly M.-P., Jordan J.H., Meléndez G.C. et al. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy. J Cardiovasc Magn Reson 2017;19(1):59. DOI: 10.1186/s12968-017-0373-3.

25. Srikanthan K., Klug R., Tirona M. et al. Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients. J Clin Exp Cardiolog 2017;8(3):507. DOI: 10.4172/2155–9880.1000507.

26. Cardinale D., Sandri M.T. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53(2):121–9. PMID: 20728699. DOI: 10.1016/j.pcad.2010.04.002.

27. Ky B., Carver J.R. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin 2011;7(3):323–31. PMID: 21749884. DOI: 10.1016/j.hfc.2011.03.002.

28. Legha S.S., Benjamin R.S., Mackay B. et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96(2):133–9. PMID: 7059060.

29. Torti F.M., Bristow M.R., Howes A.E. et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983;99(6):745–9. PMID: 6651020.

30. Gianni L., Munzone E., Capri G. et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13(11):2688–99. PMID: 7595726. DOI: 10.1200/ JCO.1995.13.11.2688.

31. Boyle E.M., Morschhauser F. Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Saf 2015;14(4):601–7. PMID: 25716061. DOI: 10.1517/14740338.2015.1010505.

32. O’Brien M.E., Wigler N., Inbar M. et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15(3):440–9. PMID: 14998846.

33. Swain S.M., Whaley F.S., Gerber M.C. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15(4):1318–32. PMID: 9193323. DOI: 10.1200/JCO. 1997.15.4.1318.

34. Curigliano G., Cardinale D., Suter T. et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 (Suppl 7):vii155–66. PMID: 22997448. DOI: 10.1093/annonc/mds293.

35. Jones S.E., Savin M.A., Holmes F.A. et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381–7. PMID: 17135639ю DOI: 10.1200/JCO.2006.06.5391.

36. Holmes F.A., Rowinsky E.K. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 2001;28(4 Suppl 12):8–14. PMID: 11552225.

37. Salvatorelli E., Menna P., Cascegna S. et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 2006;318(1): 424–33. PMID: 16614166. DOI: 10.1124/jpet.106.103846.

38. Floyd J.D., Nguyen D.T., Lobins R.L. et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23:7685–96.

39. Tan-Chiu E., Yothers G., Romond E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811–9. PMID: 16258083. DOI: 10.1200/JCO.2005.02.4091.

40. Samuel Avila M., Ayub-Ferreira S.M., de Barros Wanderley M.R. et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity(The CECCY Trial). J Am Coll Cardiol 2018;71(20):2281–90. DOI: 10.1016/j. jacc. 2018.02.049.

41. Семиглазова Т.Ю., Телетаева Г.М., Козявин Н.А., Загатина А.В. Диагностика и профилактика кардиотоксичности у больных раком молочной железы с позиций онколога и кардиолога. Опухоли женской репродуктивной системы 2017;13(3):17–27. [Semiglazova T.Yu., Teletaeva G.M., Kozyavin N.A., Zagatina A.V. Diagnosis and prevention of cardiotoxicity in patients with breast cancer from the standpoint of an oncologist and a cardiologist. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2017;13(3): 17–27. (In Russ.)]. DOI: 10.17650/1994- 4098-2017-13-3-17-27.

42. Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT). Available at: https://clinicaltrials.gov/ ct2/show/NCT01988571.

43. Tamargo J., Caballero R., Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015;38(2):129–52. PMID: 25577497. DOI: 10.1007/s40264-014-0258-4.

44. Sanchez A.P., Gilbert C., Spears D. et al. Incidence, diagnosis, and management of qt prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc 2017;6(12):e007724. PMID: 29217664. DOI: 10.1161/JAHA.117.007724.

45. Zhang Y., Post W.S., Blasco-Colmenares E. et al. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011;22(5):660–70. PMID: 21709561. DOI: 10.1097/EDE.0b013e318225768b.

46. Finn R.S., Martin M., Rugo H.S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925–36.

47. Hortobagyi G.N., Stemmer S.M., Burris H.A. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375(18):1738–48. PMID: 27717303. DOI: 10.1056/NEJMoa1609709.

48. Tripathy D., Im S.A., Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018. PII: S1470– 2045(18)30292–4. PMID: 29804902. DOI: 10.1016/S1470–2045(18) 30292–4.

49. Bell T., Ward M., Harnett J. et al. Proportion of women with HR+/HER2– metastatic breast cancer that may be at risk of QT prolongation in a large US Health Care Database. Presented at the 35th Annual Miami Breast Cancer Conference (MBCC), March 8–11, 2018; Miami Beach, FL, USA.

50. Durairaj C., Ruiz-Garcia A., Gauthier E.R. et al. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs 2018;29(3):271–80. PMID: 29360661. DOI: 10.1097/CAD.0000000000000589.

51. Cristofanilli M., Turner N.C., Bondarenko I. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17(4):425–39. PMID: 26947331. DOI: 10.1016/S1470-2045(15)00613-0.

52. Priori S.G., Blomstrom-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36(41):2793–867. PMID: 26320108. DOI: 10.1093/eurheartj/ehv316.

53. Tamargo J., Caballero R., Delpon E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 2015;38(2):129–52. PMID: 25577497. DOI: 10.1007/s40264-014-0258-4.

54. Strevel E.L., Ing D.J., Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25(22):3362–71. PMID: 17664484. DOI: 10.1200/JCO.2006.09.6925.